TOPIC: Cardiology; oncology

ACCREDITATION TYPE: 1 AMA PRA Category 1 Credit(s)™ ; 1 ABIM MOC medical knowledge point

RELEASE DATE: November 8, 2021

EXPIRATION DATE: November 7, 2022

ESTIMATED TIME TO COMPLETE ACTIVITY: 60 minutes

PROVIDER
Jointly provided by The France Foundation and the International Cardio-Oncology Society

TARGET AUDIENCE
This educational activity is intended for the members of the cardiology and oncology healthcare teams who treat patients with cardiac amyloidosis, including physicians (cardiologists and hematologists/oncologists) and advance practice providers (nurse practitioners and PAs).

STATEMENT OF NEED
There are significant challenges associated with the diagnosis and management of cardiac amyloidosis. While considered rare, this condition is almost certainly significantly underdiagnosed. Cardiac amyloidosis is influenced by several factors (eg: sex, age, geographic location, genetic factors, etc), is clinically heterogeneous, can present as a number of other disorders (with subsequent delayed or misdiagnosis), and can take several years and visits to several different specialists before an accurate diagnosis is made.

Early diagnosis and intervention is critical (including distinguishing ATTR from AL and other amyloidosis), yet does not occur, typically as a consequence of the heterogeneity of the disease. Therapeutic options are indication-specific and are limited, but there are new and emerging agents with which clinicians may not be familiar. Given the limited awareness of CA, there is a significant need for education about CA and the importance of early multidisciplinary diagnosis and management, so that patients can have the best possible outcomes.

EDUCATIONAL ACTIVITY LEARNING OBJECTIVES
Upon completing this activity, learners should be able to:

• Identify screening methods for monoclonal gammopathy
• Discuss confirmatory methods for pathologic testing
• Explain genetic screening for familial mutations

ACTIVITY FACULTY
Roberta Shcolnik Szor, MD
Hematologist
Sao Paulo Cancer Institute
University of Sao Paulo

Keith Stockerl-Goldstein, MD
Professor of Medicine
Washington University School of Medicine
St. Louis, Missouri

Daniel Lenihan, MD
President
International Cardio-Oncology Society

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and the International Cardio-Oncology Society. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION
Physicians: The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

METHOD OF PARTICIPATION/HOW TO RECEIVE CREDIT

1. There are no fees for participating in and receiving credit for this activity
2. Review the activity objectives and CME/CE information
3. Complete the CME/CE activity
4. Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
5. Complete the CME/CE evaluation/attestation form at https://surveys.francefoundation.com/s3/9128-WEBINAR-SERIES-A-ZEBRA-OR-A-HORSE-Cardiac-Amyloidosis-Establish-the-Correct-Diagnosis-Web-3. This evaluation provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
6. Credit documentation/reporting:
• If you are requesting AMA PRA Category 1 Credit(s)™ or a certificate of participation—your CME/CE certificate will be available for download.
• If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.

DISCLOSURE POLICY
In accordance with the ACCME Standards for Commercial Support, The France Foundation and the International Cardio-Oncology Society require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and IC-OS resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and IC-OS seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and IC-OS are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, and other members at The France Foundation who control content have no relevant financial relationships to disclose.

The planners, reviewers, editors, staff, CME committee, and other members at International Cardio-Oncology Society who control content have no relevant financial relationships to disclose.

Faculty Disclosures–Activity Faculty
The faculty listed below report that they have no relevant financial relationships to disclose:

• Daniel Lenihan, MD
• Roberta Shcolnik Szor, MD

The following faculty report that they have relevant financial relationships to disclose:

• Keith Stockerl-Goldstein, MD – Consultant: Janssen

DISCLOSURE OF UNLABELED USE
TFF and IC-OS require that CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and IC-SO do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

COMMERCIAL SUPPORT ACKNOWLEDGEMENT
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., Eidos Therapeutics Inc. and Pfizer Inc.

DISCLAIMER
The France Foundation and International Cardio-Oncology Society present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, International Cardio-Oncology Society, and the commercial supporter assume no liability for the information herein.

COPYRIGHT INFORMATION
Copyright ©2021 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

• The materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
• Materials may not be published, uploaded, posted, and transmitted (other than as set forth herein), without The France Foundation's prior written permission

PRIVACY POLICY
The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.

Additional information regarding The France Foundation’s Privacy Policy can be viewed at https://www.francefoundation.com/privacy.

CONTACT INFORMATION
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.